Genmab EPS - Earnings per Share 2019-2022 | GMAB
Genmab annual and quarterly earnings per share history from 2019 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Genmab EPS for the quarter ending March 31, 2022 was $0.11, a 60.59% decline year-over-year.
- Genmab EPS for the twelve months ending March 31, 2022 was $0.56, a 57.31% decline year-over-year.
- Genmab 2021 annual EPS was $0.73, a 34.45% decline from 2020.
- Genmab 2020 annual EPS was $1.11, a 116.86% increase from 2019.
- Genmab 2019 annual EPS was $0.51, a 35.64% increase from 2018.
| Genmab Annual EPS |
| 2021 |
$0.73 |
| 2020 |
$1.11 |
| 2019 |
$0.51 |
| 2018 |
$0.38 |
| Genmab Quarterly EPS |
| 2022-03-31 |
$0.11 |
| 2021-12-31 |
$0.17 |
| 2021-09-30 |
$0.21 |
| 2021-06-30 |
$0.08 |
| 2021-03-31 |
$0.27 |
| 2020-12-31 |
$0.16 |
| 2020-09-30 |
$0.13 |
| 2020-06-30 |
$0.76 |
| 2020-03-31 |
$0.06 |
| 2019-12-31 |
$0.19 |
| 2019-09-30 |
$0.12 |
| 2019-06-30 |
$0.02 |
| 2019-03-31 |
$0.18 |
| 2018-12-31 |
$2.13 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$19.273B |
$1.349B |
|
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
|
